Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2012 / Cilt: 52 - Sayı: 1

Distribution of metabolic syndrome components in patients with non-alcoholic fatty liver disease

Non alkolik yağlı karaciğer hastalığı olan vakalarımızda metabolik sendrom bileşenlerinin dağılımı

Pages
15–21
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Body weight, height and body mass index were similar in both groups while NAFLD patients had significantly higher waist circumference compared with controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: In recent years, Non-alcoholic fatty liver disease (NAFLD), which can progress end-stage liver disease has an increasing clinical and pathological condition.
📊
Key Findings & Data:METHODS: We included 28 patients that persistently elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels for at least 3 months.
💡
Conclusion & Impact:Body weight, height and body mass index were similar in both groups while NAFLD patients had significantly higher waist circumference compared with controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: In recent years, Non-alcoholic fatty liver disease (NAFLD), which can progress end-stage liver disease has an increasing clinical and pathological condition. Metabolic syndrome (MS) is often able to accompany NAFLD and adversely affect the prognosis of this condition. The purpose of this study was to determine the prevalence of MS and its components in our subjects with diagnosis of NAFLD. METHODS: We included 28 patients that persistently elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels for at least 3 months. Subjects that tested negative for markers of viral hepatitis, autoimmune hepatitis, monotest, ceruloplasmin, alpha -1 antitrypsin were included and NAFLD was diagnosed by two radiologists with ultrasound examination (Group I). As a control group, 28 healthy volunteers included with age and gender match with the cases (GroupII). Fasting blood glucose, lipid profile, ALT, AST, total protein, albumin, uric acid, blood samples were examined. Arterial blood pressure, body weight, height, waist circumference measured and recorded. Exclusion criterias: The use of alcohol, autoimmune hepatitis, viral hepatitis, comorbid situations like renal failure, COPD, patients with diabetes and patients using drugs that can causes NAFLD. The revised NCEP ATP III diagnostic criteria was used for the diagnosis of MS. SPSS for Windows 16.0 program was used for statistical analysis. RESULTS: 28 patients with NAFLD (21 women and 7 men) mean age was 49.57±7.85. In the control group (24 women and 4 men) mean age was 47.00±7.09. Age and gender did not differ significantly between the groups (p>0.05). Body weight, height and body mass index were similar in both groups while NAFLD patients had significantly higher waist circumference compared with controls (p

Özet

GİRİŞ ve AMAÇ: Non alkolik yağlı karaciğer hastalığı (NAFLD) son dönem karaciğer hastalığına ilerleyebilen ve önemi her geçen gün daha da artan klinik ve patolojik bir durumdur. NAFLD'ye metabolik sendrom (MS) sıklıkla eşlik edebilmekte ve bu durum prognozu olumsuz yönde etkilemektedir. Bu çalışmanın amacı polikliniğimizde NAFLD tanısı alan hastalarımızda MS sıklığını ve MS bileşenlerin dağılımını incelemektir.METOD: İç hastalıkları polikliniğimizde en az 3 aydır sebat eden alanin aminotransaminaz (ALT) ve/veya aspartat aminotransaminaz (AST) yüksekliği bulunan, iki radyoloji uzmanı tarafından ultrasonografik görünüm itibariyle NAFLD lehine bulgu saptanmış, viral hepatit markırları, otoim-mün hepatit markırları, monotest, seruloplazmin, alfa-1 antitripsin tetkikleri yapılarak kronik karaciğer hastalığının diğer nedenleri dışlanmış ve bu şekilde NAFLD tanısı almış 28 hasta çalışmaya dahil edildi (Grup I). Kontrol grubu olarak yaş ve cinsiyet açısından hasta grubu ile benzerlik gösteren 28 sağlıklı gönüllü (Grup II) alındı. Olguların açlık kan şekeri, lipid profili, ALT, AST, total protein, albümin, ürik asit testleri incelendi, arter-yel kan basıncı değerleri, vücut ağırlıkları, boyları, bel çevreleri ölçülerek kaydedildi. Alkol kullanımı bulunan, viral ve/veya otoimmün hepatiti bulunan, böbrek yetmezliği, KOAH, karaciğer sirozu, DM tanıları bulunan, NAFLD'ye neden olabi- lecek ilaç kullanan hastalar çalışma dışı bırakıldı. MS tanısında NCEP ATP lll'ün 2005'de revize edilen tanı kriterleri kullanıldı. İstatistiksel analizler için SPSS for Windows 16.0 programı kullanıldı.BULGULAR: NAFLD'li 28 olgunun 21'i kadın, 7'si erkek, yaş ortalaması 49.57±7.85'di. Kontrol grubunun 24'ü kadın, 4'ü erkek, yaş ortalaması 47.00±7.09'du. Yaş ve cinsiyet açısından gruplar arasında istatistiksel anlamlı farklılık bulunmadı (p>0.05). Gruplar vücut ağırlığı, boy, beden kitle indeksi açısından benzer bulunmakla birlikte, NAFLD'li hastaların bel çevreleri kontrollere göre anlamlı yüksek bulundu (p

🔖

Cite This Article

KARATOPRAK, C., OKUROĞLU, N., ADİK, A., DEMİRTUNÇ, R., ABANONU, G. B. (2022). Distribution of metabolic syndrome components in patients with non-alcoholic fatty liver disease. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 52 - Sayı: 1, 15–21. https://ajindex.com/articles/535419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Angulo P, Lindor KD. Non-alcoholic fatty liver disease: Quan-drenial review. The Journal of Gastroenterology and Hepatology, 2002, 17 suppl. 186-190
  2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD. Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-95
  3. Bedogni G, Miglioli L, Masutti F, Tiribeili C, Marchesini G, Bel-ientani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42:44-52
  4. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45:600-6
  5. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease.QJM. 2010 Feb; 103(2):71-83 6- Kowdiey KV, Caldwell S. Nonalcoholic steatohepatitis: a twentyfirst century epidemic. J Clin Gastroenterol 2006;40:2-4
  6. Caldwell SH, Oelsner DH, Jezzani JC, Hespendheide EE. Battle EH, Driscoll CJ. Cryptogenic cirhosis. Clinical Characterization and risk factors for underling disease. Hepatology, 1990; 29: 664-669
  7. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an un-derrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289:3000-4
  8. Kasper D, Braunwald E, Fauci A, Hauser S, Lango D, Jameson JL. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Harrison's Principles of Internal Medicine. Mc Graw-Hill Medical Publishing Division
  9. Edition. 2005; 1869-1870
  10. Marchesini G, Bugianesi E, Forlani G, Cerelli F, Lenzi M, Manini R, Natale S, et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology, April 2003: Vol 37, no 4, 917-923
  11. Hamaguchi M, Kojima T, Takada N, Nakagawa T, Taniguchi H, Fuzi K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Annals of Internal Medicine. No-vomber 2005; Vol 143, Number 10. 722-728
  12. Grundy SM, Cleeman Jl, Daniels SR, Donato KA, Eckel RH. Franklin BA, Gordon DJ, Krauss RM, Savage PJ. Smith SC Jr, Spertus J A, Costa F; American Heart Association; National Heart. Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17).2735-52
  13. Onat A, Sansoy V. Metabolic syndrome, Major culprit of coronary disease among turks: Its prevalence and impact on coronary